The CardiaTec Biosciences

Cardiovascular diseases (CVDs) remain the leading global cause of death, despite decades of research. While oncology and neurodegenerative diseases have witnessed significant technological advancements, the field of CVDs has lagged behind. New technologies are urgently needed to address this gap and combat the persistent threat posed by heart diseases.

A Systems Biology Approach to Drug Discovery

CardiaTec’s proprietary platform goes beyond traditional singular omic analysis, unraveling complex relationships across various biological levels. By examining gene variation, methylation, expression, proteomic, and metabolomic functions, the company gains a deeper understanding of disease development. This systems biology approach has the potential to significantly reduce the time and cost associated with drug discovery, bringing new treatments to market more rapidly.

CardiaTec Biosciences: A Pioneer in AI-Driven Drug Discovery

Founded in 2021 by CEO Raphael Peralta, alongside CTO Prof. Namshik Han and COO Thelma Zablocki .Biosciences is at the forefront of leveraging artificial intelligence (AI) to revolutionize cardiovascular drug discovery. The company’s innovative approach involves applying AI to vast amounts of multi-omic data, enabling the identification of novel drug targets and accelerating the development of life-saving therapies.

Leaders Details

  • Raphael Peralta, CEO: With his expertise in AI and drug discovery, Raphael is driving CardiaTec’s mission to revolutionize the field of cardiovascular medicine.
  • Dr. Namshik Han, CTO: Dr. Han’s deep understanding of AI and its applications in healthcare is instrumental in developing CardiaTec’s innovative technologies.
  • Thelma Zablocki, Co-Founder: As a seasoned entrepreneur, Thelma brings valuable experience to the leadership team.

Funding Details

In a major milestone, CardiaTec Biosciences has secured £1.4 million in pre-seed funding. The investment round was led by Laidlaw Scholars Ventures and APEX Ventures, with participation from Crista Galli Ventures, o2h ventures, and Cambridge Enterprise.   

Key Highlights of the Funding Round:

  • First Investment by Laidlaw Scholars Ventures: This marks the inaugural investment by LSV, a new venture capital fund established by the Laidlaw Foundation to support businesses led by Laidlaw Scholars.
  • Focus on Patient Outcomes: The funding will be used to further develop CardiaTec’s AI-powered drug discovery platform and accelerate the development of novel treatments for cardiovascular diseases.

CardiaTec Biosciences is poised to make a significant impact on the fight against cardiovascular diseases. By harnessing the power of AI and a systems biology approach, the company is working to develop innovative treatments that can improve patient outcomes and save lives. With the recent funding round, CardiaTec is well-positioned to accelerate its research and development efforts and bring its promising therapies to market.

Website : https://www.cardiatec.ai/

Hey Savi Revolutionizes Online Fashion Shopping with £2.2M Funding